Zobrazeno 1 - 10
of 7 190
pro vyhledávání: '"N Hata"'
Autor:
Cameron S. Fraser, Johan K. E. Spetz, Xingping Qin, Adam Presser, Jonathan Choiniere, Chendi Li, Stacey Yu, Frances Blevins, Aaron N. Hata, Jeffrey W. Miller, Gary A. Bradshaw, Marian Kalocsay, Vaishali Sanchorawala, Shayna Sarosiek, Kristopher A. Sarosiek
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Immunoglobulin light chain amyloidosis is a lethal hematologic disorder driven by clonal plasma cells producing abnormal light chains that damage healthy tissues. Fraser et al. show that BH3 mimetics, which inhibit pro-survival proteins BCL-2 or MCL-
Externí odkaz:
https://doaj.org/article/af565676a38f48089f10fb446aad1c14
Autor:
Francesca Nardi, Naiara Perurena, Amy E. Schade, Ze-Hua Li, Kenneth Ngo, Elena V. Ivanova, Aisha Saldanha, Chendi Li, Prafulla C. Gokhale, Aaron N. Hata, David A. Barbie, Cloud P. Paweletz, Pasi A. Jänne, Karen Cichowski
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 16 (2023)
Despite the success of KRAS G12C inhibitors in non–small cell lung cancer (NSCLC), more effective treatments are needed. One preclinical strategy has been to cotarget RAS and mTOR pathways; however, toxicity due to broad mTOR inhibition has limited
Externí odkaz:
https://doaj.org/article/755ab4bb5edc4eaaa779ca594c91fcf4
Autor:
Tara Al Zubaidi, O. H. Fiete Gehrisch, Marie-Michelle Genois, Qi Liu, Shan Lu, Jong Kung, Yunhe Xie, Jan Schuemann, Hsiao-Ming Lu, Aaron N. Hata, Lee Zou, Kerstin Borgmann, Henning Willers
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Mutant KRAS is a common tumor driver and frequently confers resistance to anti-cancer treatments such as radiation. DNA replication stress in these tumors may constitute a therapeutic liability but is poorly understood. Here, using single-mo
Externí odkaz:
https://doaj.org/article/c9f65698ab184d44a3f15db972aba8ea
Autor:
Farideh Davoudi, Samar Ghorbanpoor, Satoshi Yoda, Xiao Pan, Giovanna Stein Crowther, Xunqin Yin, Ellen Murchie, Aaron N. Hata, Henning Willers, Cyril H. Benes
Publikováno v:
STAR Protocols, Vol 2, Iss 2, Pp 100391- (2021)
Summary: Two-dimensional (2D) culture of tumor cells fails to recapitulate some important aspects of cellular organization seen in in vivo experiments. In addition, cell cultures traditionally use non-physiological concentration of nutrients. Here, w
Externí odkaz:
https://doaj.org/article/71211847c6f34c619a6501fb7eae1612
Autor:
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical mod
Externí odkaz:
https://doaj.org/article/1fb146a2c258459e81f631757ffb5a98
Autor:
Wen Cai Zhang, Nicholas Skiados, Fareesa Aftab, Cerena Moreno, Luis Silva, Paul Joshua Anthony Corbilla, John M. Asara, Aaron N. Hata, Frank J. Slack
Publikováno v:
Cancer Gene Therapy. 29:1878-1894
In EGFR-mutant lung cancer, drug-tolerant persister cells (DTPCs) show prolonged survival when receiving EGFR tyrosine kinase inhibitor (TKI) treatments. They are a likely source of drug resistance, but little is known about how these cells tolerate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::461f519732b84aa11a629d52de1ac79d
https://doi.org/10.1038/s41417-022-00504-y
https://doi.org/10.1038/s41417-022-00504-y
Autor:
Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick Dinkelborg, Heike Pfäffle, Qi Liu, Meng Wang, Zofia Piotrowska, Lecia V. Sequist, Kerstin Borgmann, Jeffrey E. Settleman, Jeffrey A. Engelman, Aaron N. Hata, Henning Willers
Publikováno v:
Cell Reports, Vol 27, Iss 12, Pp 3422-3432.e4 (2019)
Summary: Lung cancers with oncogenic mutations in the epidermal growth factor receptor (EGFR) invariably acquire resistance to tyrosine kinase inhibitor (TKI) treatment. Vulnerabilities of EGFR TKI-resistant cancer cells that could be therapeutically
Externí odkaz:
https://doaj.org/article/b251464c40e6447c8b8f6bee0056c8c6
Autor:
Jiehui Deng, David H. Peng, David Fenyo, Hao Yuan, Alfonso Lopez, Daniel S. Levin, Mary Meynardie, Mari Quinteros, Michela Ranieri, Soumyadip Sahu, Sally C. M. Lau, Elaine Shum, Vamsidhar Velcheti, Salman R. Punekar, Natasha Rekhtman, Catríona M. Dowling, Vajira Weerasekara, Yun Xue, Hongbin Ji, Yik Siu, Drew Jones, Aaron N. Hata, Takeshi Shimamura, John T. Poirier, Charles M Rudin, Takamitsu Hattori, Shohei Koide, Thales Papagiannakopoulos, Benjamin G. Neel, Nabeel Bardeesy, Kwok-kin Wong
Publikováno v:
bioRxiv
LKB1/STK11 is a serine/threonine kinase that plays a major role in controlling cell metabolism, resulting in potential therapeutic vulnerabilities in LKB1-mutant cancers. Here, we identify the NAD+degrading ectoenzyme, CD38, as a new target in LKB1-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::664879e61c343e2d903f560a28e6eb38
https://europepmc.org/articles/PMC10153147/
https://europepmc.org/articles/PMC10153147/
Autor:
Jessica J. Lin, Henry E. Pelish, Aaron N. Hata, Monika A. Davare, Viola Zhu, Matthew D. Shair, James R. Porter, Nancy E. Kohl, John R. Soglia, Yuting Sun, Scot Mente, Satoshi Yoda, Katelyn S. Nicholson, Clare Keddy, Adam Acker, Linh Nguyen-Phuong, Anthonie J. van der Wekken, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Benjamin Besse, Anupong Tangpeerachaikul, Joshua C. Horan, Alexander Drilon
NVL-520 Modeling, Properties, Biochemical Activity, Cellular Activity, and In Vivo Activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179b478fa795d20f06c52f43443d2a80
https://doi.org/10.1158/2159-8290.22542255
https://doi.org/10.1158/2159-8290.22542255
Autor:
Jessica J. Lin, Henry E. Pelish, Aaron N. Hata, Monika A. Davare, Viola Zhu, Matthew D. Shair, James R. Porter, Nancy E. Kohl, John R. Soglia, Yuting Sun, Scot Mente, Satoshi Yoda, Katelyn S. Nicholson, Clare Keddy, Adam Acker, Linh Nguyen-Phuong, Anthonie J. van der Wekken, D. Ross Camidge, Shirish M. Gadgeel, Sai-Hong Ignatius Ou, Benjamin Besse, Anupong Tangpeerachaikul, Joshua C. Horan, Alexander Drilon
ROS1 tyrosine kinase inhibitors (TKI) have been approved (crizotinib and entrectinib) or explored (lorlatinib, taletrectinib, and repotrectinib) for the treatment of ROS1 fusion–positive cancers, although none of them simultaneously address the nee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04fc95b4f0ef39c29165338ddd307aa5
https://doi.org/10.1158/2159-8290.c.6549846
https://doi.org/10.1158/2159-8290.c.6549846